In a second step, immunogenicity of identified epitopes is verified through T cell restimulation assays of peripheral blood mononuclear cells from the sequenced patient (84, 86–89) or MHC-I (85, 90) and -II (91, 92) tetramers or multimers detecting tumor-neoantigen-specific CD8+ and CD4+ T cells, respectively. This evidence concerns the gene CD4 and neoplasm.